Latest News - Atopic Dermatitis

Monday, October 09, 2017 | Personnel/Company News, PracticalDermatology.com, Product Launches and Updates, Avene

Eau Thermale Avène Expands its #AveneHope Program

In recognition of Eczema Awareness Month and National Bullying Prevention Awareness Month this October, Eau Thermale Avène is expanding its #AveneHope program…

Read the full story

Monday, October 02, 2017 | PracticalDermatology.com, Research and Publications

Study IDs Racial and Ethnic Disparities in Pediatric Eczema Treatment

White children in the US are more likely to see a doctor for treatment of eczema than black children, despite the fact that the disease is likely more severe among minorities. Research from the Per…

Read the full story

Monday, September 18, 2017 | PracticalDermatology.com, Research and Publications

U.K Survey Reveals Eczema Treatment Knowledge Gap

Two thirds of UK eczema patients don’t understand that bacteria play a crucial role in their condition despite studies showing that Staphylococcus aureus is present on the skin in of more than 7…

Read the full story

Monday, September 18, 2017 | PracticalDermatology.com, Regeneron, Sanofi

EADV News: Positive Study Results for Dupixent® (dupilumab) in Patients With Moderate-to-Severe AD

Dupixent with topical corticosteroids (TCS) significantly improved measures of overall disease severity, skin clearing, itching, and patient reported quality of life measure in adults with moderate-to…

Read the full story

Thursday, September 14, 2017 | PracticalDermatology.com, Research and Publications, JAK inhibitors

Lilly’s Baricitinib Performs Well in Phase 2 AD Study

Lilly’s experimental JAK inhibitor Baricitinib in combination with a mid-potency topical corticosteroid (TCS) significantly improved the signs and symptoms of moderate-to-severe atopic dermatiti…

Read the full story

Wednesday, September 13, 2017 | PracticalDermatology.com, Product Launches and Updates, Research and Publications

Vanda's Tradipitant Improves Itch and Disease Severity in AD Patients

Vanda Pharmaceuticals Inc.’s tradipitant improved the intensity of the worst itch patients experienced, as well as atopic dermatitis (AD) disease severity,  according to results from an eig…

Read the full story

Monday, September 11, 2017 | Phase 3/4 Trials, PracticalDermatology.com, PracticalDermatology.com, Research and Publications

Lilly to Present New Data for Olumiant® and Taltz® at EADV

Eli Lilly and Company will present Phase 2 safety and efficacy data evaluating Olumiant® (baricitinib) for the treatment of moderate-to-severe atopic dermatitis (Lilly and Incyte Corporation …

Read the full story

Wednesday, September 06, 2017 | Personnel/Company News, PracticalDermatology.com, Research and Publications, Atopic Derm, Atopic Dermatitis

AD Breakthrough? Medimetriks’ MM36 Achieves Rapid Itch Relief, Safety in Phase 2 Study

Medimetriks’ PDE4 inhibitor, MM36, appears to be safe, well-tolerated and provides rapid itch relief when applied twice daily to pediatric and adolescent atopic dermatitis (AD) patients, accordi…

Read the full story

Thursday, August 31, 2017 | FDA Approval/Clearance, Healthcare Trends, Phase 3/4 Trials, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Research and Publications

GBI Research: Global Dermatology Pipeline Will See Shift Toward Increased Use of Biologics

The global dermatology pipeline, which currently comprises 850 products with a disclosed stage of development, is primarily made up of drugs at an early stage of development, with the late stages of t…

Read the full story

Tuesday, August 15, 2017 | PracticalDermatology.com, PracticalDermatology.com, PuraCap

PuraCap Pharmaceuticals Introduces EpiCeram Quad Pack

PuraCap® Pharmaceutical is introducing the EpiCeram® Controlled Release Skin Barrier Emulsion Quad Pack, which contains four 100-gram airless pumps. EpiCeram® is a US Food and Drug Admi…

Read the full story

Tuesday, August 01, 2017 | PracticalDermatology.com

Glenmark Pharmaceuticals Reports Positive Phase 2a Data for GBR 830 for Atopic Dermatitis

Glenmark Pharmaceuticals shared positive data from a Phase 2a study of GBR 830, an investigational, anti-OX40 monoclonal antibody, for the treatment of atopic dermatitis (AD). The study evaluated the …

Read the full story

Thursday, July 27, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, PracticalDermatology.com, Product Launches and Updates, Atopic Derm, Atopic Dermatitis , Eczema, Psoriasis, Valeant NJ

Valeant’s Newly Minted Ortho Dermatologic Unit Makes Big Splash at Summer AAD

It’s go big or go home for the newly re-branded Valeant Ortho Dermatologic division. At the 2017 American Academy of Dermatology in New York City, the company will officially launch …

Read the full story

Monday, July 10, 2017 | Personnel/Company News, PracticalDermatology.com, PracticalDermatology.com, Celgene

Dr. Jacqualyn Fouse Named Executive Chairman of Dermavant

Dr. Jacqualyn "Jackie" Fouse is the new Executive Chairman of Dermavant Sciences. Part of the Roivant Sciences family of companies, Dermavant Sciences is developing and, upon regulatory a…

Read the full story

Wednesday, June 28, 2017 | PracticalDermatology.com, National Eczema Association

HydroLotion Scores National Eczema Association Seal of Acceptance

Theraplex Company’s HydroLotion Daily Skin Moisturizer now has the National Eczema Association (NEA) Seal of Acceptance. The light-weight moisturizer for the face and body is hypoallergenic, …

Read the full story

Monday, June 19, 2017 | PracticalDermatology.com, Research and Publications, Eczema

CARD11 Mutations May Lead to AD

Researchers have identified mutations in a gene called CARD11 that may lead to atopic dermatitis. Their findings, reported in Nature Genetics, also suggest that some of these defects…

Read the full story
Load More